<SEC-DOCUMENT>0001214659-20-002918.txt : 20200326
<SEC-HEADER>0001214659-20-002918.hdr.sgml : 20200326
<ACCEPTANCE-DATETIME>20200325190051
ACCESSION NUMBER:		0001214659-20-002918
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200326
DATE AS OF CHANGE:		20200325
EFFECTIVENESS DATE:		20200326

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES INC
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19731
		FILM NUMBER:		20743531

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			United Church Funds, Inc.
		CENTRAL INDEX KEY:			0001739344
		IRS NUMBER:				237092477
		STATE OF INCORPORATION:			CT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		475 RIVERSIDE DRIVE
		STREET 2:		SUITE 1020
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10115
		BUSINESS PHONE:		(212) 729-2600

	MAIL ADDRESS:	
		STREET 1:		475 RIVERSIDE DRIVE
		STREET 2:		SUITE 1020
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10115
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>r325201px14a6g.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="unitedchurchfund_smlogo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PROXY MEMORANDUM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>To: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gilead Sciences, Inc. Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.6in"><B>Subject:
</B>Shareholder proposal on an Independent Chair</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-align: justify; text-indent: -0.6in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Date: </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 25, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.6in"><B>Contact: </B>Katie McCloskey,
Director Social Responsibility, United Church Funds, katie.mccloskey@ucfunds.org</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6in; text-indent: -0.6in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Vote FOR Proposal #4 to Require an Independent
Chair at<BR>
Gilead Sciences, Inc. (NASDAQ: GILD) Meeting Date: May 6, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We urge you to vote FOR Proposal #4 asking the board to require
an independent director as chair of Gilead Sciences, Inc. (GILD) (&ldquo;Gilead&rdquo;) at the May 6, 2020 Annual Meeting. This
proposal is not intended as a referendum on Daniel O&rsquo;Day&rsquo;s leadership as CEO or fitness as a director, but solely on
his continued service as chair. We believe a structure where the CEO runs the business and is accountable to a board led by an
independent chair is in the best interests of the company&rsquo;s shareholders for the following reasons:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Eliminates Structural Conflicts of Interest in Dual Role</U>. The
management of a complex global pharmaceutical company is a full-time job. It is unrealistic &ndash; and needlessly complicated
-- to expect one person to perform well as CEO on top of his or her responsibilities for providing rigorous board oversight. An
independent board chair eliminates the structural conflicts of interest caused by the CEO essentially being his or her own boss
and clarifies where the authority of the CEO ends and responsibility of the independent board members begins. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Significant Governance Concern Resulting from Board Failure to
Oversee Material Risks</U>. In light of potentially material legal, regulatory, financial and reputational risks, as well as controversies
and legal challenges facing the company (as described in more detail below), we are concerned that the board is not providing the
necessary oversight of the company&rsquo;s culture, strategy, and risk management. . Adopting best governance practices, including
an independent board chair, would help strengthen that oversight.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that independent board leadership would be especially
useful at Gilead, given the business risks related to its drugs to treat Human Immunodeficiency Virus (&ldquo;HIV&rdquo;). The
high price of HIV drug Truvada has generated controversy, spurred calls to weaken or invalidate patents involving the drug, and
focused attention on alleged anti-competitive practices designed to preserve Gilead&rsquo;s monopoly. Outside the U.S., where generic
Truvada is available, a one-month supply costs less than $6, but the U.S. cost averages over $1,600.<FONT STYLE="font-size: 10pt"><SUP>i</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Truvada is used for pre-exposure prophylaxis (PrEP), in which
patients at high risk of contracting HIV take medication daily to prevent infection. Citing Truvada&rsquo;s high price and the
major role the federal government played in developing PrEP, advocates pressed the federal government to use patent remedies to
make PrEP less expensive&mdash;accusing Gilead of &ldquo;price-gouging&rdquo;&mdash;and more widely available.<FONT STYLE="font-size: 10pt"><SUP>ii</SUP></FONT>
Late last year, the federal government sued Gilead for infringing government patents related to PrEP, and the Patent Trial and
Appeals Board recently dismissed a separate review Gilead had sought regarding PrEP patents.<FONT STYLE="font-size: 10pt"><SUP>iii</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gilead has been dogged by allegations that it declined to pursue
candidates for new, safer HIV drugs in order to generate more profits from older drugs like Truvada while they still enjoyed patent
exclusivity. HIV patients who asserted that they suffered unnecessary side effects, including kidney and bone problems, as a result
of the delay have filed suit in federal court, and similar cases brought by patients have been filed in state courts.<FONT STYLE="font-size: 10pt"><SUP>iv</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gilead is also responding to subpoenas and requests for information
concerning its sales and marketing practices for its HIV and Hepatitis C drugs from the U.S. Attorney Offices for the District
of Massachusetts, the Eastern District of Pennsylvania and the Southern District of New York; the California Department of Insurance;
and the Alameda County District Attorney&rsquo;s Office.<FONT STYLE="font-size: 10pt"><SUP>v</SUP></FONT> Class action lawsuits
have been filed against Gilead in federal court on behalf of end-payor purchasers, alleging anti-competitive practices involving
the company&rsquo;s HIV drugs, in violation of federal and state antitrust laws and state consumer protection laws.<FONT STYLE="font-size: 10pt"><SUP>vi</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These legal challenges and investigations have generated substantial
media attention, which raise concerns about reputational and financial harm to the company and its shareholders.<FONT STYLE="font-size: 10pt"><SUP>vii</SUP></FONT>
In light of these concerns, Gilead&rsquo;s board should promote rigorous oversight by adopting best practice governance policies,
including an independent board chair. More U.S. companies are separating the chair and CEO positions, those combining the positions
reached a decade low of 45.6% in 2018.<FONT STYLE="font-size: 10pt"><SUP>viii</SUP></FONT> As boards separate these positions,
they are increasingly moving towards requiring that the chair be an independent director. According to the 2019 U.S. Spencer Stuart
Board Index, the number of S&amp;P 500 companies with independent board chairs has more than doubled over the past decade, to now
include one-third of the companies.<FONT STYLE="font-size: 10pt"><SUP>ix</SUP></FONT> Among the 18 Biotechnology/Pharmaceutical
companies listed in the Spencer Stuart report, seven have independent chairs, including Biogen Idec, Regeneron Pharmaceuticals,
Perrigo Company and Nektar Therapeutics.<FONT STYLE="font-size: 10pt"><SUP>x</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In our view, a combined chair/CEO diminishes the quality of
board discussions. According to PwC&rsquo;s 2019 Annual Corporate Directors Survey, 57% of over 700 public company directors surveyed
indicated that it was more difficult for dissent to be voiced on one or more issues in the boardroom when there was a combined
chair/CEO.<SUP>xi</SUP> In a recent <I>Harvard Business Review</I> article, Joseph Mandato and William Devine argued in favor
of separating the chair and CEO roles, citing findings from interviews they conducted with CEOs, board chairs, investors and founders.
They argued that separation &ldquo;can strengthen the quality of the questions the corporation asks itself,&rdquo; which improves
risk management.<SUP>xii</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gilead also notes the historical lack of a majority vote for
this proposal as a reason not to implement it. The average vote for the past six times that the proposal appeared in Gilead&rsquo;s
proxy statement was over 38 percent, which is significantly higher than the proposal&rsquo;s average vote at S&amp;P 1500 companies
during this same period.<SUP>xiii</SUP> This suggests that Gilead&rsquo;s investors have a greater than average concern about
the absence of an independent chair at the company, particularly given the material risk and governance concerns noted above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vote FOR Proposal #4 to require an independent <FONT STYLE="font-size: 10pt">chair
at Gilead.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center; border: Black 1pt solid; width: 100%"><B>This is not a proxy solicitation, to vote your proxy. Please DO NOT send us your proxy card, as
    it will not be accepted.</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;_______________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>i</SUP> James Krellenstein et al., &ldquo;Why Don&rsquo;t
More Americans Use PrEP?&rdquo;, <I>The New York Times</I>, July 16, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>ii</SUP> <I>See</I> https://www.nbcnews.com/feature/nbc-out/breakthepatent-how-hiv-activists-are-going-after-gilead-s-prep-n892891;
James Krellenstein et al., &ldquo;Why Don&rsquo;t More Americans Use PrEP?&rdquo;, <I>The New York Times</I>, July 16, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>iii</SUP> <I>See</I> https://www.hhs.gov/about/news/2019/11/06/us-files-patent-infringement-lawsuit-against-gilead-pre-exposure-prophylaxis-hiv.html;
https://www.statnews.com/pharmalot/2020/02/05/gilead-hiv-patents-truvada-cdc/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>iv</SUP> <I>See</I>, <I>e.g.</I>, Christopher Rowland,
&ldquo;Gilead is accused of cutting anti-competitive deals to extend profit on HIV drug combinations&rdquo;, <I>The Washington
Post</I>, May 14, 2019, <I>available</I> at https://www.washingtonpost.com/business/economy/gilead-is-accused-of-cutting-anti-competitive-deals-to-extend-profit-on-hiv-drug-cocktails/2019/05/14/94e79c56-75ad-11e9-bd25-c989555e7766_story.html;
Eric Sagonowsky, &ldquo;Gilead tries&mdash;and fails&mdash;to dodge lawsuit claiming it delayed safer HIV meds&rdquo;, <I>FiercePharma</I>,
May 14, 2019, <I>available</I> at https://www.fiercepharma.com/pharma/gilead-fails-to-convince-judge-to-toss-hiv-drug-case; and
Arlene Weintraub, &ldquo;U.S. representatives to Gilead: Did your donation of free HIV prevention drug Truvada have strings attached?&rdquo;,
<I>FiercePharma</I>, June 27, 2019, <I>available</I> at https://www.fiercepharma.com/pharma/us-reps-to-gilead-did-your-donation-free-hiv-prevention-drug-truvada-have-strings-attached;
https://www.marketwatch.com/press-release/ahf-calls-on-gilead-to-set-up-10-billion-fund-for-victims-harmed-by-its-tdf-based-drugs-2019-07-17</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>v</SUP> Filing on Form 10-K filed on Feb. 25, 2020, at
77-78.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>vi</SUP> <I>Id</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>vii</SUP> <I>See</I> Ed Silverman, &ldquo;Activists seek
to block a Gilead patent extension on a lucrative HIV drug&rdquo;, <I>Pharmalot</I>, December 6, 2019, <I>available</I> at https://www.statnews.com/pharmalot/2019/12/06/gilead-hiv-patents-aids/;
&ldquo;US: Gilead hit with antitrust suit over price-fixing HIV drugs&rdquo;, <I>Competition Policy International</I> (excerpted
from <I>Life Sciences Intellectual Property Review</I>) both dated January 16, 2020, <I>available</I> at https://www.competitionpolicyinternational.com/us-gilead-hit-with-antitrust-suit-over-price-fixing-hiv-drugs/;
and Eric Sagonowsky, &ldquo;Gilead loses again in PrEP patent fight with HHS, sending dispute to federal court&rdquo;, <I>FiercePharma</I>,
February 21, 2020, <I>available</I> at https://www.fiercepharma.com/pharma/gilead-loses-another-prep-patent-challenge-against-hhs-sending-dispute-to-federal-court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>viii</SUP> <I>See</I> Mengqi Sun, &ldquo;More U.S. Companies
Separating Chief Executive and Chairman Roles<I>&rdquo; Wall Street Journal, available </I>at https://www.wsj.com/articles/more-u-s-companies-separating-chief-executive-and-chairman-roles-11548288502</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>ix</SUP><I>See</I> &ldquo;2019 U.S. Spencer Stuart Board
Index&rdquo;, at 8-9 (https://www.spencerstuart.com/-/media/2019/ssbi-2019/us_board_index_2019.pdf).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>x</SUP> <I>Id</I>., at 48-49.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xi</SUP> <I>See</I> http://www.insurance.ca.gov/diversity/41-ISDGBD/GBDExternal/upload/pwc-2019-annual-corporate-directors-survey-full-report-2.pdf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xii</SUP> Joseph Mandate and William Devine, &ldquo;Why
the CEO Shouldn&rsquo;t Also be the Board Chair,&rdquo; Harvard Business Review, Mar. 4, 2020, available at https://hbr.org/2020/03/why-the-ceo-shouldnt-also-be-the-board-chair.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>xiii</SUP> <I>See</I> the 2016 and 2019 &ldquo;Annual
Corporate Governance Reviews&rdquo; published by Georgeson, <I>available</I> at https://www.georgeson.com/us/Documents/acgr/acgr2016.pdf
(at 23) and https://www.georgeson.com/us/news-insights/annual-corporate-governance-review (at 14).</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>unitedchurchfund_smlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 unitedchurchfund_smlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MSL]$NCW=CWJBOHC@"B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@
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M#XV_#_X@^-?AO\+?$M_=?#WQ/>:#=Z"(X!=:C=VZ1.PM_P!YM(82C;O*G@Y
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M_P 8/VP/ _P:\-?#OQ-XA\)ZY-'\2?$%CI&CV\-LB36LUU"TL9G21U* *I#
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MS2M:TV"_TV[C!VSV\T:R1N,]BK _C2EW1.6U:T+X6LO>@E9])1V3_#4^??\
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MVE-[\J_(QQ4>3$32[L**] YPHH ** "B@ HH ** "B@ HH ** "B@ HH **
M"B@ HH ** "B@ HH ** "@C(H ^.?VQO#>B:1^W?\,/%?CO2;:Z\/ZS#'87
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M",8145LCA;<G=A15 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
*!10 44 %% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
